[CAS NO. 218791-21-0] Imisopasemmanganese
PRODUCTS SPECIFICATIONS [218791-21-0]
DESCRIPTION [218791-21-0]
Overview
| MDL | MFCD09954128 |
|---|---|
| Molecular Weight | 479.35 |
| Molecular Formula | C21H31Cl2MnN5 |
| SMILES | [Cl-][Mn+2]1234([Cl-])[N]5=C6C=CC=C5CN1[C@]7([H])CCCC[C@@]7([H])N2CCN3[C@@](CCCC8)([H])[C@]8([H])N4C6 |
Summary
Imisopasem manganese (M40403) is a stable non-peptidyl mimetic of manganese superoxide MnSOD .
In Vitro
Imisopasem manganese is a small molecule, synthetic manganese containing superoxide dismutase mimetic (SODm) that removes superoxide anions without interfering with other reactive species known to be involved in inflammatory responses (e.g. nitric oxide, NO and peroxynitrite, ONOO-) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Imisopasem manganese is a small-molecule superoxide dismutase mimetic that has shown efficacy in animal model disease states in which superoxide anions are thought to play a key role. Imisopasem manganese inhibits the inflammatory response following the intrapleural injection of carrageenan in rats. All parameters of inflammation are attenuated by Imisopasem manganese except for NOx, PGE2 and IL-10 which remains unaltered [1] . Decreased apoptosis of the large and particularly the small bowel and marked recovery of both lymphoid and hematopoietic tissues occurs in the Imisopasem manganese pre-treated mice. Imisopasem manganese is effective in reducing TBI-induced tissue destruction and has potential as a new radioprotective agent [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00101621 | MetaPhore Pharmaceuticals |
Cancer|Pain
|
August 2004 | Phase 2 |
| NCT00033956 | MetaPhore Pharmaceuticals |
IL-2 Induced Hypotension
|
December 2001 | Phase 1|Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
H 2 O : 25 mg/mL ( 52.15 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.0862 mL | 10.4308 mL | 20.8616 mL |
| 5 mM | 0.4172 mL | 2.0862 mL | 4.1723 mL |
| 10 mM | 0.2086 mL | 1.0431 mL | 2.0862 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 8.33 mg/mL (17.38 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
References
- [1] Salvemini D, et al. Pharmacological manipulation of the inflammatory cascade by the superoxide dismutase mimetic,M40403. Br J Pharmacol. 2001 Feb;132(4):815-27.
- [2] Masini E, et al. Protective effects of M40403, a selective superoxide dismutase mimetic, in myocardial ischaemia and reperfusion injury in vivo. Br J Pharmacol. 2002 Jul;136(6):905-17.